RAD
RADIOPHARM FPO [RAD]
Healthcare · ASX Small Cap
$0.0090 +0.0%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 2 consecutive scansFirst seen: 2026-03-09
Get alerts when RAD triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Stochastic is deep in oversold territory — bounce conditions forming
- Sitting near support — this level has held before and could attract buyers again
- Took a hit — down 10.0% over the last 5 days
- Lagging the Small Ords index — relative strength of 0.77, underperforming its peers
- Volatility is contracting — like a spring being compressed, breakouts often follow
- Critical cash runway (0.3 quarters)
- Low P/S ratio (2.9x)
- Revenue in sharp decline (-28%)
- EPS estimates revised upward (+10pts)
- Near 52-week low (0% of range)
- Small-cap ($20-100M)
- Substantial holder(s) ceased (1)
- Turned profitable (NPAT positive from results)
- Sentiment is mixed — no strong consensus either way
- Altman Z-Score distress zone (-2.19 < 1.81, low-confidence approx)
- Penny stock risk ($0.009)
- Beneish M-Score 55.78 > -1.78: likely earnings manipulation
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Long-term momentum is negative — down 48% over the past year
- Revenue declining at -28% — the top line is shrinking
- The bigger volume days are the down days — volume-weighted momentum is negative (-5.84%/day)
Recent Catalysts
NONE RAD Announces Positive Data from RAD301 P1 Imaging Trial
NONE Appendix 4E and Preliminary Final Report
NONE Change of Director's Interest Notices x 4
HIGH Ceasing to be a substantial holder
Announcement tone +3pts
Recent ASX Announcements
| 2026-09-08 | RAD Announces Positive Data from RAD301 P1 Imaging Trial |
| 2026-08-28 | Appendix 4E and Preliminary Final Report PRICE SENSITIVE |
| 2026-08-27 | Change of Director's Interest Notices x 4 |
| 2026-08-25 | RAD Doses First Patient in Second Cohort of BetaBart (RV-01) PRICE SENSITIVE |
| 2026-08-24 | Ceasing to be a substantial holder |
Key Metrics
$39.0M
Market Cap
10.3M
Avg Volume
0.7x
Vol Ratio
$0.01 — $0.04
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-174.7%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 68% |
| L | Leader vs Laggard | laggard | RS: -32 |
| I | Institutional Sponsorship | weak | Inst: 9% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
110 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track RAD and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required